ISSN 0820-3946
5 papers in the library · 244 citations · publishing 2015-2022
Canadian Medical Association Journal December 18, 2022 Kevin Zannese 9 citations
Alberta will soon become the first province to regulate psychedelic-assisted therapy. But, as with cannabis, momentum for medical access to psychedelics is outpacing research to guide their use. Earlier this year, Health Canada amended its Special Access Program to allow physicians to request
Canadian Medical Association Journal November 14, 2021 Greg Basky 7 citations
Research interest in the therapeutic use of psilocybin, or "magic mushrooms," is growing alongside a "wild west" of dispensaries in Canada and the United States. The past decade has seen a revival of research exploring the clinical use of psychedelics in treating depression, addiction,
Canadian Medical Association Journal February 16, 2016 Wm. Jeptha Davenport 14 citations
Tupper and colleagues highlight reasons for renewed interest in the use of psychedelic drugs as adjuncts to psychotherapy.[1][1] Clinicians have an interest in extending research into headache medicine, especially the treatment of cluster headaches (prevalence roughly 0.1%) when episodes are
Canadian Medical Association Journal September 8, 2015 Kenneth W. Tupper, Evan Wood, Richard Yensen et al. 189 citations
In clinical research settings around the world, renewed investigations are taking place on the use of psychedelic substances for treating illnesses such as addiction, depression, anxiety and posttraumatic stress disorder (PTSD). Since the termination of a period of research from the 1950s to the
Canadian Medical Association Journal August 4, 2015 Erika Dyck 25 citations
Psychedelics fell from medical grace nearly half a century ago, but recent activity suggests that some researchers have "high hopes" for their return.[1][1],[2][2] Over 60 years ago, Albert Hofmann at Sandoz Pharmaceutical Laboratories in Switzerland first synthesized lysergic acid diethylamide